Arcus Biosciences
RCUS
200 hedge funds and large institutions have $1.09B invested in Arcus Biosciences in 2022 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 73 increasing their positions, 65 reducing their positions, and 21 closing their positions.
95% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 21
12% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 65
9% more funds holding
Funds holding: 183 → 200 (+17)
0.22% more ownership
Funds ownership: 72.72% → 72.94% (+0.22%)
20% less capital invested
Capital invested by funds: $1.37B → $1.09B (-$281M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
56% less call options, than puts
Call options by funds: $6.61M | Put options by funds: $14.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$33.1M |
| 2 |
FAM
Fred Alger Management
New York
|
+$17.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$17M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$13.3M |
| 5 |
BlackRock
New York
|
+$12.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$18.7M |
| 2 |
PA
Perceptive Advisors
New York
|
-$17.4M |
| 3 |
FC
Finepoint Capital
Boston,
Massachusetts
|
-$16.9M |
| 4 |
State Street
Boston,
Massachusetts
|
-$16.4M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$11.4M |
RCUS Hedge Fund Activity: Q4 2022 in Review
200 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q4 2022, worth a combined $1.09B — down 20% from $1.37B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new RCUS positions and 21 closed out — a net gain of 20 holders — while 73 added to existing stakes and 65 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $33.1M. The largest seller was PFM Health Sciences, cutting an estimated $18.7M.
- 200 institutional investors held Arcus Biosciences (RCUS) as of Q4 2022, up from 183 in Q3 2022.
- Funds reported $1.09B of Arcus Biosciences stock for Q4 2022, down 20% quarter-over-quarter.
- 41 funds opened new Arcus Biosciences positions in Q4 2022 and 21 closed out, a net change of +20 holders.
- The largest Arcus Biosciences buyer in Q4 2022 was Woodline Partners, an estimated $33.1M added.
- The largest Arcus Biosciences seller in Q4 2022 was PFM Health Sciences, an estimated $18.7M sold.
Based on aggregated 13F filings for Q4 2022.